Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator
Citations Over TimeTop 10% of 2016 papers
Abstract
The cooperation of adaptive immunity with pharmacologic therapy influences cancer progression. Though non-steroidal anti-inflammatory drugs (NSAIDs) have a long history of cancer prevention, it is unclear whether adaptive immune system affects the action of those drugs. In present study, we revealed a novel immunological mechanism of sulindac. Our data showed that sulindac had substantial efficacy as a single agent against 4T1 murine breast cancer and prolonged the survival of tumor-bearing mice. However, in the athymic nude mice, sulindac treatment was ineffective. Further in vivo T cell subsets depletion experiments showed that CD8+ T lymphocytes deficiency reversed the anti-tumor effect of sulindac. In addition, sulindac significantly reduced M2 macrophages recruitment, cancer-related inflammation and tumor angiogenesis. Our results advance our understanding of the mechanisms of NSAIDs, and more importantly, this will provide insight into rational drug design or antitumor immunotherapy.
Related Papers
- → Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis(1996)46 cited
- → Chemoprevention of Colon Cancer by DFMO, Sulindac, and NO-Sulindac Administered Individually or in Combinations in F344 Rats(2023)14 cited
- → A protective effect of sulindac against chemically‐induced primary colonic tumours in mice(1988)136 cited
- → SULINDAC HEPATOTOXICITY: EFFECTS OF ACUTE AND CHRONIC EXPOSURE(1985)29 cited
- → A KINETIC STUDY OF SULINDAC IN THE ELDERLY(1987)5 cited